Abstract
Psychotropic drugs, like antipsychotics and antidepressants, are often associated with metabolic side effects such as weight gain and an increased risk of the development of diabetes and an atherogenic lipid profile. These adverse effects not only bear a high cardiovascular risk and lead to higher morbidity and mortality, but are an additional burden to mentally ill patients and can be a decisive factor for the compliance and, consequently, the success of the therapy. Second generation antipsychotics (SGAs), in particular, clozapine and olanzapine, lead to significant weight gain and impair glucose metabolism. Despite the availability of newer SGAs, such as aripiprazole, which are considered to be less prone to cause metabolic side effects, olanzapine is still one of the most prescribed SGAs worldwide. Antidepressant drugs may also induce weight again and diabetes even though the literature is contradictory, probably due to different receptor affinities. This review aims to provide an overview of the metabolic side effects caused by commonly used psychotropic drugs and give insight into underlying mechanisms.
Keywords: Antidepressants, antipsychotics, diabetes, glucose metabolism, insulin resistance, psychotropic drugs, weight gain.
Current Diabetes Reviews
Title:The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Volume: 9 Issue: 5
Author(s): Ramona Al-Zoairy, Claudia Ress, Alexander Tschoner, Susanne Kaser and Christoph Ebenbichler
Affiliation:
Keywords: Antidepressants, antipsychotics, diabetes, glucose metabolism, insulin resistance, psychotropic drugs, weight gain.
Abstract: Psychotropic drugs, like antipsychotics and antidepressants, are often associated with metabolic side effects such as weight gain and an increased risk of the development of diabetes and an atherogenic lipid profile. These adverse effects not only bear a high cardiovascular risk and lead to higher morbidity and mortality, but are an additional burden to mentally ill patients and can be a decisive factor for the compliance and, consequently, the success of the therapy. Second generation antipsychotics (SGAs), in particular, clozapine and olanzapine, lead to significant weight gain and impair glucose metabolism. Despite the availability of newer SGAs, such as aripiprazole, which are considered to be less prone to cause metabolic side effects, olanzapine is still one of the most prescribed SGAs worldwide. Antidepressant drugs may also induce weight again and diabetes even though the literature is contradictory, probably due to different receptor affinities. This review aims to provide an overview of the metabolic side effects caused by commonly used psychotropic drugs and give insight into underlying mechanisms.
Export Options
About this article
Cite this article as:
Al-Zoairy Ramona, Ress Claudia, Tschoner Alexander, Kaser Susanne and Ebenbichler Christoph, The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990067
DOI https://dx.doi.org/10.2174/15733998113099990067 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diet and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets The Therapeutical Effect of Chinese Medicine for the Treatment of Atherosclerotic Coronary Heart Disease
Current Pharmaceutical Design Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial
Reviews on Recent Clinical Trials Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy Management of Obesity in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Oxidized-LDL and Paraoxonase-1 As Biomarkers of Coronary Artery Disease in Patients with Sleep-Disordered Breathing
Current Medicinal Chemistry Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Editorial from Guest Editors [Hot Topic: Children with Congenital Heart Disease (Guest Editors: Kris De Boeck and Tony Reybrouck)]
Current Respiratory Medicine Reviews Comparative Study of Nutritional and Phytochemical Attributes of Andrographis paniculata, Bryophyllum pinnatum and Clitoria ternatea for Nutraceutical Applications
Current Nutrition & Food Science Preface [Hot Topic: The Roller Coaster of Antioxidant Therapy (Guest Editor: Francesco Visioli)]
Current Medicinal Chemistry Obesity in the Childhood: A Link to Adult Hypertension
Current Pharmaceutical Design Adiposity and Alzheimers Disease
Current Alzheimer Research Machine Learning Based Support System for Students to Select Stream (Subject)
Recent Advances in Computer Science and Communications Postoperative Care of the Transplanted Patient
Current Cardiology Reviews